U.S. markets closed

Immatics N.V. (IMTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.21-0.35 (-2.79%)
At close: 4:00PM EDT
Sign in to post a message.
  • J
    James
    BioCopy AG is now collaborating with the company and its tech (ultra-high-throughput) will be implemented as part of the XCEPTOR platform. The goal is to enable the characterisation of more than 5,000 different TCR-peptide-HLA interactions, to facilitate large preclinical safety screening for TCR based therapies.
  • B
    BrianM
    New price target Goldman Sachs $17
    Bullish
  • J
    Jerry
    Phase 1 People...... don't know why people fall for the trap. This will come down to 13 or less today
  • J
    Jay Powie
    $IMTX
    Continues its rise from the bottom.
    Highlights:

    1. High profile investors in the PIPE: Perceptive Advisors, Redmile Group, Federated Hermes Kaufmann Funds, RTW Investments, Sphera Funds, and an additional healthcare focused investor, as well as current existing Company shareholders including dievini Hopp BioTech, AT Impf and Wellington Partners.
    2. Immatics received gross proceeds of up to $252 million at the closing of the transaction.
    3. Cash expected at closing gives Immatics 3+ years of cash runway, so additional capital raises shouldn’t be on the calendar for quite some time, post-combination close.
    4. The Company has several large-scale collaborations with global leaders in the pharmaceutical industry. Strategic partnerships with Amgen, Genmab, BMS, GSK.
    5. Chart broke SMA 50 last week.
    6. Next resistance on a chart is $11.50. Once broken, clear path to $15.
    7. Large number of presentations in the next 30 days.
    Broken! $11.98 Now
  • A
    Anonymous
    welcome all to this board. i‘m an immunotherapy enthusiast; both for the sake of cancer patients, as well as from a stock market perspective.

    IMTX has several good shots at targeting solid tumors with cell therapies as well as biologics. quite unique platform, still diversified portfolio.

    looking at adaptimmune and iovance, any decent response rates in solid tumors - even rare ones like sarcomas - will push market cap of IMTX north of 1b usd. currently just below 300m according to google.

    good luck to all and looking forward to discussing science and markets!
  • N
    NOEL
    If a stock breaches its 52-week high, there's a strong chance that significant gains are ahead.
  • J
    James
  • B
    BrianM
    Finally showing a little life. Maybe a sign for 2021.
  • A
    Anonymous
    Data on IMA201/202/203 expected q1 or h1 2021. will any partial response trigger a run up?
    Bullish
  • J
    Joe
    Amazing breakthrough !!!!
  • D
    Diesel
    watch IMTX and SSKN and buy at the dip today
  • I
    Isiah
    At the end of the third quarter, a total of 22 of the hedge funds tracked by Insider Monkey were long this stock, a change of 22 from one quarter earlier.
    Bullish
  • J
    Jay Powie
    IMTX Immatics NV Gaps Up this morning +6.31% to $$11.80from $11.10!
    WHY? Immatics granted patent for immunotherapy against several tumors The United States Patent and Trademark Office posted on its website a patent granted to Immatics for an immunotherapy against several tumors.
    https://app.dimensions.ai/details/patent/US-9101585-B2
    Immatics Corporate Presentation https://investors.immatics.com/static-files/4b347408-8d2c-4c25-b5cd-d07c9a8e142e
  • S
    Scott
    Check out the news today. Possible cure for cancer??
  • B
    BrianM
    If anyone is looking there are 62,908,617 shares outstanding currently so at $12.35 the market cap is $777 million. Of that market cap the company has $300 million in cash. Had to dig through the SEC reports to find the info. There is also the outstanding warrants that will potentially add another 7,187,500 shares at some point in the future and are exercised in August. I am long and will be holding for at least some shares for the next year.
    Bullish
  • R
    Roetes
    the german investor base is very encouraging
    Bullish
  • C
    Christopher
    lets see some volume on this!
  • J
    Jerry
    Watch they will issue new shares after market. mark my word
  • J
    James
    Just another PUMPER....
    BEWARE...
  • H
    Hello
    So during the analysis of this company, perceptive indicated that it was undervalued relative to other companies in this field, there was a list of those companies in the filings

    Only thing Can figure for the downward stock price is little interest until it receives some news or analyst coverage, most really don’t know if even is new public company